Skip to content
OpenCapital
Get started

Aprea Therapeutics, Inc. APRE Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Revenue$3.3KIn line
EPS-$0.32Beat by $0.06
Revenue estimate$3.3K
EPS estimate-$0.38

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$253.0K
EPS estimate-$0.23

Versus estimates

Revenue

Q1 2026$281.0K
Q4 2025$3.3KIn line
Q3 2025$1.8KQ2 2025$118.1KQ1 2025$162.5KQ4 2024$205.8KMiss by $19.2K

Diluted EPS

Q1 2026-$0.22Beat by $0.01
Q4 2025-$0.32Beat by $0.06
Q3 2025-$0.47Miss by $0.36Q2 2025-$0.53Beat by $0.24Q1 2025-$0.66Miss by $0.01Q4 2024-$0.49Beat by $0.20

Ask the moment Aprea Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aprea Therapeutics, Inc. report Q4 2025 earnings?
Aprea Therapeutics, Inc. (APRE) reported Q4 2025 earnings on March 16, 2026 before market open.
What were Aprea Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Aprea Therapeutics, Inc. reported revenue of $3.3K and eps of $-0.32 for Q4 2025.
Did Aprea Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $3.3K by -. EPS beat the consensus estimate of $-0.38 by $0.06.
How did Aprea Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 98.4% from $205.8K a year earlier and eps grew 34.7% from $-0.49.
Where can I find Aprea Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-028046) and the 10-K periodic report (0001104659-26-028068) directly on SEC EDGAR. The filing index links above go to sec.gov.